US › Healthcare

Pyxis Oncology Inc (PYXS)

US · Healthcare · Biotechnology

$3.16+3.95%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-23.3M
Profit YoY
-10.0%
EPS
$-0.37
EPS estimate
$-0.35

EPS came in at -0.37 against a street estimate of -0.35 — a miss of 5.7%.

Key statistics

Market cap
$167.9M
Forward P/E
0.0
P/B
5.37
Book value
$0.50
EPS (TTM)
$-1.30
52-week high
$5.55
52-week low
$0.97
50-day MA
$2.24
200-day MA
$2.34
Beta
1.31

Analyst view

Analysts rate Pyxis Oncology Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $6.75.

Shareholding

Insiders
13.60%
Institutions
42.83%

Largest institutional holders

FundStake
Pfizer Inc11.10%
LAURION CAPITAL MANAGEMENT LP7.89%
GordonMD Global Investments LP6.51%
Vanguard Capital Management, LLC3.21%
Palo Alto Investors, LLC1.59%
Atle Fund Management AB1.53%
683 Capital Management LLC1.41%
Renaissance Technologies Corp1.40%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pyxis Oncology Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.